Literature DB >> 28674053

In Vitro Activity of Ceftolozane-Tazobactam and Other Antimicrobial Agents against Burkholderia cepacia Complex and Burkholderia gladioli.

Dale M Mazer1, Carol Young2, Linda M Kalikin3, Theodore Spilker3, John J LiPuma4.   

Abstract

We tested the activities of ceftolozane-tazobactam and 13 other antimicrobial agents against 221 strains of Burkholderia cepacia complex and Burkholderia gladioli Most strains (82%) were cultured from persons with cystic fibrosis, and most (85%) were recovered since 2011. The ceftolozane-tazobactam MIC was ≤8 μg/ml for 77% of the strains. However, the MIC range was broad (≤0.5 to >64 μg/ml; MIC50/90, 2/32 μg/ml). Significant differences in susceptibility to some antimicrobial agents were observed between species.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Burkholderia; ceftolozane; cystic fibrosis

Mesh：

Substances：

Year:  2017        PMID： 28674053      PMCID： PMC5571321          DOI： 10.1128/AAC.00766-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.

Authors:  Joseph L Kuti; Rebecca S Pettit; Natalie Neu; Jeffrey J Cies; Craig Lapin; Marianne S Muhlebach; Kimberly J Novak; Sean T Nguyen; Lisa Saiman; David P Nicolau
Journal:  Diagn Microbiol Infect Dis       Date:  2015-05-01       Impact factor: 2.803

2.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

3.  In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.

Authors:  Patrick Grohs; Gary Taieb; Philippe Morand; Iheb Kaibi; Isabelle Podglajen; Marie Lavollay; Jean-Luc Mainardi; Fabrice Compain
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Development of a recA gene-based identification approach for the entire Burkholderia genus.

Authors:  George W Payne; Peter Vandamme; Sara H Morgan; John J Lipuma; Tom Coenye; Andrew J Weightman; T Hefin Jones; Eshwar Mahenthiralingam
Journal:  Appl Environ Microbiol       Date:  2005-07       Impact factor: 4.792

Review 5.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

6.  In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

Authors:  W A Craig; D R Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-12-28       Impact factor: 5.191

7.  Microbiological and epidemiological features of clinical respiratory isolates of Burkholderia gladioli.

Authors:  Christine Segonds; Patricia Clavel-Batut; Michelle Thouverez; Dominique Grenet; Alain Le Coustumier; Patrick Plésiat; Gérard Chabanon
Journal:  J Clin Microbiol       Date:  2009-03-18       Impact factor: 5.948

8.  Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III.

Authors:  Tom Coenye; Theodore Spilker; Alissa Martin; John J LiPuma
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

9.  Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).

Authors:  David J Farrell; Robert K Flamm; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

10.  Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates.

Authors:  David R Snydman; Laura A McDermott; Nilda V Jacobus
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191
  10 in total
  7 in total

Review 1.  Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.

Authors:  Nadim G El Chakhtoura; Elie Saade; Alina Iovleva; Mohamad Yasmin; Brigid Wilson; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2018-01-16       Impact factor: 5.091

2.  In Vitro Susceptibility of Ceftolozane-Tazobactam against Burkholderia pseudomallei.

Authors:  Elaine Chan; Paolo Martelli; Suk-Wai Hui; Jade L L Teng; Susanna K P Lau; Patrick C Y Woo
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

3.  In Vitro Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-Tazobactam.

Authors:  A Van Dalem; M Herpol; F Echahidi; C Peeters; I Wybo; E De Wachter; P Vandamme; D Piérard
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 4.  Burkholderia cepacia Complex Bacteria: a Feared Contamination Risk in Water-Based Pharmaceutical Products.

Authors:  Mariana Tavares; Mariya Kozak; Alexandra Balola; Isabel Sá-Correia
Journal:  Clin Microbiol Rev       Date:  2020-04-15       Impact factor: 26.132

5.  A rapid screening method for the detection of specialised metabolites from bacteria: Induction and suppression of metabolites from Burkholderia species.

Authors:  Gordon Webster; Cerith Jones; Alex J Mullins; Eshwar Mahenthiralingam
Journal:  J Microbiol Methods       Date:  2020-09-14       Impact factor: 2.363

6.  In Vitro Activity of Ceftolozane/Tazobactam vs Nonfermenting, Gram-Negative Cystic Fibrosis Isolates.

Authors:  Jeanne B Forrester; Lisa L Steed; Barbara A Santevecchi; Patrick Flume; Gloria E Palmer-Long; John A Bosso
Journal:  Open Forum Infect Dis       Date:  2018-07-02       Impact factor: 3.835

Review 7.  Nosocomial Pneumonia in the Era of Multidrug-Resistance: Updates in Diagnosis and Management.

Authors:  Elena Xu; David Pérez-Torres; Paraskevi C Fragkou; Jean-Ralph Zahar; Despoina Koulenti
Journal:  Microorganisms       Date:  2021-03-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.